Abstract
Schizophrenia patients have difficulties identifying odors, possibly a marker of cognitive and social impairment. This study investigated olfactory identification (OI) differences between patients and controls, related to cognitive and social functioning in childhood and adolescence, to present state cognition and to present state social cognition. 132 schizophrenia patients and 128 healthy controls were assessed on OI performance with the Sniffin’ Sticks task. Multiple regression analyses were conducted investigating OI in association with cognitive and social functioning measures in childhood/adolescence and in association with IQ, memory, processing speed, attention, executive functioning, face recognition, emotion recognition and theory of mind. Patients had reduced OI performance compared to controls. Also, patients scored worse on childhood/adolescence cognitive and social functioning, on present state cognitive functioning and present state social cognition compared to controls. OI in patients and controls was significantly related to cognitive and social functioning in childhood/adolescence, to present state cognition and to present state social cognition, with worse functioning being associated with worse OI. In this study, findings of worse OI in patients relative to controls were replicated. We also showed associations between OI and cognitive and social functioning which are not specific to schizophrenia.
| Original language | English |
|---|---|
| Pages (from-to) | 147-151 |
| Number of pages | 5 |
| Journal | Psychiatry Research |
| Volume | 266 |
| DOIs | |
| Publication status | Published - Aug 2018 |
| Externally published | Yes |
Bibliographical note
Funding Information:Lieuwe de Haan has received research funding form Eli Lilly and honoraria for educational programs from Eli Lilly, Jansen Cilag, BMS, Astra Zeneca. Rene S. Kahn is or has been a member of DSMB for Janssen, Otsuka, Sunovion and Roche. Wiepke Cahn is or has been an unrestricted research grant holder with, or has received financial compensation as an independent symposium speaker or as a consultant from Eli Lilly, BMS, Lundbeck, Sanofi-Aventis, Janssen-Cilag, AstraZeneca and Schering-Plough. All other authors report no conflicts of interest.
Funding Information:
The infrastructure for the GROUP study is funded through the Geestkracht programme of the Dutch Health Research Council (ZON–MW, grant number 10–000–1001 ). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Publisher Copyright:
© 2018 Elsevier B.V.
